Pfizer share news, announcements and annual reports
NSE: PFIZERBSE: 500680Pharmaceuticals & BiotechnologySmall Cap
Pfizer Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1966 on BSE, Apr 1999 on NSE
Last close ₹3,687.80down ₹72.00 (1.92%)BSE ₹3,687.05
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,759.80.
30 Oct: open ₹3,760.00, high ₹3,776.90, low ₹3,668.10
52-week range of traded prices to 30 Oct 2026
₹3,589.00Low, 23 Oct 2026₹5,346.00High, 30 Oct 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,871 Cr327th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.95
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.01
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.03%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,12450.8% delivered
Pfizer board meetings
106 filed, newest first. Page 3 of 3.
Mar 2008
24 Mar · Board meeting
To consider the Unaudited Financial Results of the Company for the 1st Quarter ended February 29, 2008.
Feb 2008
18 Feb · Board meeting
To consider the Audited Statement of Accounts of the Company for the year ended November 30, 2007 and to recommend dividend thereon.
Sep 2007
13 Sep · Board meeting
Inter-alia to consider the Unaudited Financial Results for the 3rd quarter ended August 31, 2007.
Jun 2007
21 Jun · Board meeting
To consider the Unaudited Financial Results of the Company for the 2nd Quarter ended May 31, 2007.
Mar 2007
14 Mar · Board meeting
To consider the Unaudited Financial Results of the Company for the 1st Quarter ended February 28, 2007.
Jan 2007
12 Jan · Board meeting
To consider the Audited Statement of Accounts of the Company for the year ended November 30, 2006 and to recommend dividend thereon.